"We are planning our next set ... early next year," Bill Spetch, operations and integration manager of NASA’s International Space Station (ISS) program, said of spacewalks during a press ...

FILE – This undated photo released by the Roscosmos State Space Corporation shows the International Space Station (ISS). Russia’s Roscosmos state corporation on Wednesday reported an air leak in the ...

From holes in robotic arm to cracks in the window, astronauts have been complaining about the state of the International Space Station (ISS) for years. A NASA report this week admitted that ...

And that's not the only cause for concern, as the space agency has warned that the ISS is at risk of being pelted with micro-meteors and space debris. The air leak is located in the Russian ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

We recently compiled a list of the 8 Unstoppable Stocks That Could Make You Richer. In this article, we are going to take a ...

A NASA astronaut who just returned from the International Space Station has been hospitalized for an unspecified medical condition but remains stable, the US space agency said Friday. The four ...

Boeing's Starliner spacecraft returned uncrewed last month. Wilmore and Williams are scheduled to leave the ISS in February 2025 on board SpaceX Crew-9. Read next Follow us on: ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...